166 related articles for article (PubMed ID: 26512451)
1. Electron-dense deposit in renal transplant patients on eculizumab may be drug-derived.
Brealey JK; Cassidy J
Ultrastruct Pathol; 2016; 40(1):2-6. PubMed ID: 26512451
[TBL] [Abstract][Full Text] [Related]
2. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies.
McCaughan JA; O'Rourke DM; Courtney AE
Am J Transplant; 2012 Apr; 12(4):1046-51. PubMed ID: 22233157
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab for dense deposit disease and C3 glomerulonephritis.
Bomback AS; Smith RJ; Barile GR; Zhang Y; Heher EC; Herlitz L; Stokes MB; Markowitz GS; D'Agati VD; Canetta PA; Radhakrishnan J; Appel GB
Clin J Am Soc Nephrol; 2012 May; 7(5):748-56. PubMed ID: 22403278
[TBL] [Abstract][Full Text] [Related]
4. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
[TBL] [Abstract][Full Text] [Related]
5. Pathology after eculizumab in dense deposit disease and C3 GN.
Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC
Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144
[TBL] [Abstract][Full Text] [Related]
7. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
[TBL] [Abstract][Full Text] [Related]
8. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
Stegall MD; Diwan T; Raghavaiah S; Cornell LD; Burns J; Dean PG; Cosio FG; Gandhi MJ; Kremers W; Gloor JM
Am J Transplant; 2011 Nov; 11(11):2405-13. PubMed ID: 21942930
[TBL] [Abstract][Full Text] [Related]
9. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
10. Eculizumab in Pediatric Dense Deposit Disease.
Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
[TBL] [Abstract][Full Text] [Related]
11. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
[TBL] [Abstract][Full Text] [Related]
12. An unusual pattern of peritubular capillary injury involving apoptosis in a renal transplant patient.
Brealey JK; Cassidy J; Manavis J
Ultrastruct Pathol; 2018; 42(4):323-332. PubMed ID: 29897310
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
[TBL] [Abstract][Full Text] [Related]
14. The use of eculizumab in renal transplantation.
Barnett AN; Asgari E; Chowdhury P; Sacks SH; Dorling A; Mamode N
Clin Transplant; 2013; 27(3):E216-29. PubMed ID: 23516966
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
Nester CM; Brophy PD
Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
[TBL] [Abstract][Full Text] [Related]
16. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab in dense-deposit disease after renal transplantation.
Sánchez-Moreno A; De la Cerda F; Cabrera R; Fijo J; López-Trascasa M; Bedoya R; Rodríguez de Córdoba S; Ybot-González P
Pediatr Nephrol; 2014 Oct; 29(10):2055-9. PubMed ID: 24908321
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab and recurrent C3 glomerulonephritis.
Gurkan S; Fyfe B; Weiss L; Xiao X; Zhang Y; Smith RJ
Pediatr Nephrol; 2013 Oct; 28(10):1975-81. PubMed ID: 23689905
[TBL] [Abstract][Full Text] [Related]
19. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient.
Chehade H; Rotman S; Matter M; Girardin E; Aubert V; Pascual M
Pediatrics; 2015 Feb; 135(2):e551-5. PubMed ID: 25624380
[TBL] [Abstract][Full Text] [Related]
20. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL
Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
